65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update.
Endocr Relat Cancer
; 25(8): T159-T169, 2018 08.
Article
in En
| MEDLINE
| ID: mdl-29535142
Temozolomide is an alkylating chemotherapeutic agent used in malignant neuroendocrine neoplasia, melanoma, brain metastases and an essential component of adjuvant therapy in the treatment of glioblastoma multiforme and anaplastic astrocytoma. Since 2006, it has been used for the treatment of pituitary carcinomas and aggressive pituitary adenomas. Here, we discuss the current indications and results of temozolomide therapy in pituitary tumors, as well as frequently asked questions regarding temozolomide treatment, duration of therapy, dosage, tumor recurrence and resistance.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pituitary Neoplasms
/
Antineoplastic Agents, Alkylating
/
Temozolomide
Limits:
Animals
/
Humans
Language:
En
Journal:
Endocr Relat Cancer
Journal subject:
ENDOCRINOLOGIA
/
NEOPLASIAS
Year:
2018
Document type:
Article
Affiliation country:
Colombia
Country of publication:
United kingdom